Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report
Abstract Background Primary aldosteronism (PA) is an adrenal gland disease, that induces increased secretion of the mineralocorticoid, aldosterone, resulting in symptoms such as hypertension. This study reports a patient with agoraphobia and panic attacks, associated with PA. This patient’s psychiat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-023-05275-w |
| _version_ | 1797647178667130880 |
|---|---|
| author | Reoto Kijima Hirofumi Tesen Ryohei Igata Naomichi Okamoto Reiji Yoshimura |
| author_facet | Reoto Kijima Hirofumi Tesen Ryohei Igata Naomichi Okamoto Reiji Yoshimura |
| author_sort | Reoto Kijima |
| collection | DOAJ |
| description | Abstract Background Primary aldosteronism (PA) is an adrenal gland disease, that induces increased secretion of the mineralocorticoid, aldosterone, resulting in symptoms such as hypertension. This study reports a patient with agoraphobia and panic attacks, associated with PA. This patient’s psychiatric symptoms improved after treatment with eplerenone, a mineralocorticoid receptor antagonist. Case presentation The patient was a 40-year-old female with agoraphobia, which refers to the irrational fear of situations that may cause anxiety, and panic attacks characterized by profuse sweating, palpitations, and generalized weakness. She was diagnosed with hypertension from PA. Subsequently, she received treatment with eplerenone, which improved her agoraphobia and panic attacks. Conclusions There have been no previous reports on PA associated with agoraphobia and panic attacks that improved with pharmacotherapy. Patients with agoraphobia and panic attacks should be evaluated for PA. In patients with PA, pharmacotherapy with eplerenone should be considered. |
| first_indexed | 2024-03-11T15:13:29Z |
| format | Article |
| id | doaj.art-340c3651900a4715aaca2d98da4c40f8 |
| institution | Directory Open Access Journal |
| issn | 1471-244X |
| language | English |
| last_indexed | 2024-03-11T15:13:29Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Psychiatry |
| spelling | doaj.art-340c3651900a4715aaca2d98da4c40f82023-10-29T12:31:56ZengBMCBMC Psychiatry1471-244X2023-10-012311310.1186/s12888-023-05275-wAgoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case reportReoto Kijima0Hirofumi Tesen1Ryohei Igata2Naomichi Okamoto3Reiji Yoshimura4Department of Psychiatry, University of Occupational and Environmental HealthDepartment of Psychiatry, University of Occupational and Environmental HealthDepartment of Psychiatry, University of Occupational and Environmental HealthDepartment of Psychiatry, University of Occupational and Environmental HealthDepartment of Psychiatry, University of Occupational and Environmental HealthAbstract Background Primary aldosteronism (PA) is an adrenal gland disease, that induces increased secretion of the mineralocorticoid, aldosterone, resulting in symptoms such as hypertension. This study reports a patient with agoraphobia and panic attacks, associated with PA. This patient’s psychiatric symptoms improved after treatment with eplerenone, a mineralocorticoid receptor antagonist. Case presentation The patient was a 40-year-old female with agoraphobia, which refers to the irrational fear of situations that may cause anxiety, and panic attacks characterized by profuse sweating, palpitations, and generalized weakness. She was diagnosed with hypertension from PA. Subsequently, she received treatment with eplerenone, which improved her agoraphobia and panic attacks. Conclusions There have been no previous reports on PA associated with agoraphobia and panic attacks that improved with pharmacotherapy. Patients with agoraphobia and panic attacks should be evaluated for PA. In patients with PA, pharmacotherapy with eplerenone should be considered.https://doi.org/10.1186/s12888-023-05275-wAgoraphobiaPanic AttacksPrimary aldosteronismMineralocorticoid |
| spellingShingle | Reoto Kijima Hirofumi Tesen Ryohei Igata Naomichi Okamoto Reiji Yoshimura Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report BMC Psychiatry Agoraphobia Panic Attacks Primary aldosteronism Mineralocorticoid |
| title | Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report |
| title_full | Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report |
| title_fullStr | Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report |
| title_full_unstemmed | Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report |
| title_short | Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report |
| title_sort | agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone a case report |
| topic | Agoraphobia Panic Attacks Primary aldosteronism Mineralocorticoid |
| url | https://doi.org/10.1186/s12888-023-05275-w |
| work_keys_str_mv | AT reotokijima agoraphobiaandpanicattackscomplicatedbyprimaryaldosteronismimprovedbytreatmentwitheplerenoneacasereport AT hirofumitesen agoraphobiaandpanicattackscomplicatedbyprimaryaldosteronismimprovedbytreatmentwitheplerenoneacasereport AT ryoheiigata agoraphobiaandpanicattackscomplicatedbyprimaryaldosteronismimprovedbytreatmentwitheplerenoneacasereport AT naomichiokamoto agoraphobiaandpanicattackscomplicatedbyprimaryaldosteronismimprovedbytreatmentwitheplerenoneacasereport AT reijiyoshimura agoraphobiaandpanicattackscomplicatedbyprimaryaldosteronismimprovedbytreatmentwitheplerenoneacasereport |